Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina

被引:51
作者
Uruena, Analia
Pippo, Tomas
Sol Betelu, Maria
Virgilio, Federico
Giglio, Norberto [1 ]
Gentile, Angela
Garcia Jimenez, Salvador [2 ]
Jauregui, Barbara [3 ]
Clark, Andrew D. [4 ]
Diosque, Maximo
Vizzotti, Carla
机构
[1] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina
[2] Org Panamer Salud, Buenos Aires, DF, Argentina
[3] Pan Amer Hlth Org, Washington, DC USA
[4] London Sch Hyg & Trop Med, London WC1, England
关键词
Pneumococcal conjugate vaccine; Cost effectiveness; Argentina; NONTYPABLE HAEMOPHILUS-INFLUENZAE; PROTEIN-D; PHID-CV; OTITIS-MEDIA; VACCINATION; CHILDREN; DISEASE; IMMUNOGENICITY; SAFETY;
D O I
10.1016/j.vaccine.2011.04.111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule. Methodology: The integrated TRIVAC vaccine cost-effectiveness model from Pan American Health Organization's ProVac Initiative (Version 1.0.65) was used to assess the health outcomes of 20 successive cohorts from birth to 5 years of age. PCV-10 and PCV-13 were each compared to a scenario assuming no PCV vaccination. A 3 + 1 (three doses + booster) schedule and a vaccination price of US$ 20.75 per dose was assumed in the base case for both vaccines. Results: Introduction of PCV-13 rather than PCV-10 would increase the number of life years gained (LYG) by at least 10%. The number of LYG (and LYG after adjustment for DALY morbidity weights) was 56,882 (64,252) for PCV-10 compared to 65,038 (71,628) for PCV-13. From the health system perspective, the cost per DALY averted was US$ 8973 and US$ 10,948 for PCV-10 and PCV-13 respectively, and US$ 8546 and US$ 10,510 respectively, after incorporating costs saved by households. When PCV13 was compared to PCV10 directly, the additional benefits of PCV-13 was conferred at a cost of US$ 28,147 per DALY averted. Cost-effectiveness was influenced mainly by vaccine price, serotype replacement, pneumonia mortality and discount rate. Conclusion: Routine vaccination against S. pneumoniae in Argentina would be cost-effective with either PCV-10 or PCV-13. PCV-13, with higher coverage of local serotypes, would prevent more cases of pneumonia, invasive pneumococcal disease, sequelae and deaths with a higher number of LYG and DALYs averted, but PCV-10, due its higher impact in the prevention of AOM, would save more costs to the healthcare system. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4963 / 4972
页数:10
相关论文
共 41 条
  • [1] AMPOFO K, 2008, 48 ANN ICAAC IDSA 46
  • [2] BAKIR J, 2001, ARCH ARGENT PEDIAT, V99
  • [3] OUTCOMES OF BACTERIAL-MENINGITIS IN CHILDREN - A METAANALYSIS
    BARAFF, LJ
    LEE, SI
    SCHRIGER, DL
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (05) : 389 - 394
  • [4] The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity
    Bermal, Nancy
    Szenborn, Leszek
    Chrobot, Andrej
    Alberto, Edison
    Lommel, Patricia
    Gatchalian, Salvacion
    Dieussaert, Ilse
    Schuerman, Lode
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) : S89 - S96
  • [5] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [6] Safety and Reactogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Routine Childhood Vaccines
    Chevallier, Bertrand
    Vesikari, Timo
    Brzostek, Jerzy
    Knuf, Markus
    Bermal, Nancy
    Aristegui, Javier
    Borys, Dorota
    Cleerbout, Jan
    Lommel, Patricia
    Schuerman, Lode
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) : S109 - S118
  • [7] DEWALS P, 2008, 48 ANN ICAAC IDSA 46
  • [8] Diez-Domingo J, 2009, PEDIATR INFECT DIS J, V28, pe167
  • [9] ESPOSITO S, 2009, PEDIATR INFECT DIS J, V28, pE169
  • [10] Larraz GG, 2010, REV PANAM SALUD PUBL, V28, P92, DOI 10.1590/S1020-49892010000800004